Appendix C

Statement of Task

An ad hoc planning committee will organize and conduct a public workshop to examine the process for evaluating evidence for genomic applications. The workshop goal is to evaluate how evidence for genomic applications is gathered and assessed for clinical decision making, reimbursement decisions, and guideline development in the absence of an ideal information base. The workshop will also address how evidence is evaluated for determining what secondary genome sequencing information should be returned to patients. Current models will be evaluated to advance discussions among diverse stakeholder groups which may include academic researchers, industry and professional society representatives, clinicians, patients, payers, and laboratory test developers. The planning committee will develop the workshop agenda, select speakers and discussants, and moderate the discussions. An individually authored summary of the workshop will be prepared by a designated rapporteur in accordance with institutional policy and procedures.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 97
Appendix C Statement of Task An ad hoc planning committee will organize and conduct a public workshop to examine the process for evaluating evidence for genomic applications. The workshop goal is to evaluate how evidence for genomic applications is gathered and assessed for clinical decision making, reimbursement decisions, and guideline development in the absence of an ideal information base. The workshop will also address how evidence is evaluated for determining what secondary genome sequencing information should be returned to patients. Current models will be evaluated to advance discussions among diverse stakeholder groups which may include academic researchers, industry and professional society representatives, clinicians, patients, payers, and laboratory test developers. The planning committee will develop the workshop agenda, select speakers and discussants, and moderate the discussions. An individually authored summary of the workshop will be prepared by a designated rapporteur in accordance with institutional policy and procedures. 97

OCR for page 97